Header Logo

Connection

Nicola Klein to Male

Back to Details
This is a "connection" page, showing publications Nicola Klein has written about Male.
Nicola Klein
Connection Strength
3.718
Male
  1. Adjuvanted vs High-Dose Influenza Vaccines in Older US Adults: A Cluster Randomized Crossover Study. JAMA Netw Open. 2026 May 01; 9(5):e2610120.
    View in: PubMed
    Score: 0.092
  2. Effectiveness of 5-pertussis-component tetanus, diphtheria, and acellular pertussis (Tdap5) vaccination in pregnancy at preventing infant pertussis. Am J Obstet Gynecol. 2026 Apr; 234(4):1172-1182.
    View in: PubMed
    Score: 0.089
  3. Effectiveness of Nirsevimab Against RSV and RSV-Related Events in Infants. Pediatrics. 2025 Aug 01; 156(2).
    View in: PubMed
    Score: 0.087
  4. Influenza Vaccination During Pregnancy and Infant Influenza in the First 6 Months of Life. Obstet Gynecol. 2025 Jun 26; 146(2):e36-e42.
    View in: PubMed
    Score: 0.087
  5. Incidence and Risk of Coronavirus Disease 2019 Hospitalization Among Unvaccinated Children. Influenza Other Respir Viruses. 2024 Oct; 18(10):e70022.
    View in: PubMed
    Score: 0.082
  6. Immunogenicity and Safety of Extended-Interval 2-Dose Regimens of 9vHPV Vaccine. Pediatrics. 2024 Aug 01; 154(2).
    View in: PubMed
    Score: 0.082
  7. Influenza Vaccine Effectiveness Against Influenza A-Associated Emergency Department, Urgent Care, and Hospitalization Encounters Among US Adults, 2022-2023. J Infect Dis. 2024 Jul 25; 230(1):141-151.
    View in: PubMed
    Score: 0.081
  8. Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. Vaccine. 2022 08 19; 40(35):5153-5159.
    View in: PubMed
    Score: 0.071
  9. Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA Vaccination in Preventing COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Nonimmunocompromised Children and Adolescents Aged 5-17 Years - VISION Network, 10 States, April 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Mar 04; 71(9):352-358.
    View in: PubMed
    Score: 0.069
  10. Identification and description of mumps cases in a non-outbreak setting and evaluation of the effectiveness of mumps-containing vaccines over time. Hum Vaccin Immunother. 2020 12 01; 16(12):3098-3102.
    View in: PubMed
    Score: 0.061
  11. Vaccine effectiveness of cell-culture relative to egg-based inactivated influenza vaccine during the 2017-18 influenza season. PLoS One. 2020; 15(2):e0229279.
    View in: PubMed
    Score: 0.060
  12. Parental risk factors for fever in their children 7-10 days after the first dose of measles-containing vaccines. Hum Vaccin Immunother. 2020 04 02; 16(4):875-880.
    View in: PubMed
    Score: 0.059
  13. Long-term effectiveness of zoster vaccine live for postherpetic neuralgia prevention. Vaccine. 2019 08 23; 37(36):5422-5427.
    View in: PubMed
    Score: 0.057
  14. Antibody persistence and booster response following MenACWY-CRM vaccination in children as assessed by two different assay methods. Vaccine. 2019 07 26; 37(32):4460-4467.
    View in: PubMed
    Score: 0.057
  15. Acellular Pertussis Vaccine Effectiveness Over Time. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.057
  16. Immunogenicity and safety of the quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine (MenACWY-TT) in splenectomized or hyposplenic children and adolescents: Results of a phase III, open, non-randomized study. Vaccine. 2018 04 19; 36(17):2356-2363.
    View in: PubMed
    Score: 0.052
  17. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine. 2018 04 12; 36(16):2133-2138.
    View in: PubMed
    Score: 0.052
  18. Lot-to-lot consistency, safety and immunogenicity of 3 lots of Haemophilus influenzae type b conjugate vaccine: results from a phase III randomized, multicenter study in infants. Vaccine. 2017 06 16; 35(28):3564-3574.
    View in: PubMed
    Score: 0.049
  19. Waning protection following 5 doses of a 3-component diphtheria, tetanus, and acellular pertussis vaccine. Vaccine. 2017 06 08; 35(26):3395-3400.
    View in: PubMed
    Score: 0.049
  20. Asthma exacerbations among asthmatic children receiving live attenuated versus inactivated influenza vaccines. Vaccine. 2017 05 09; 35(20):2668-2675.
    View in: PubMed
    Score: 0.049
  21. Risk factors and familial clustering for fever 7-10days after the first dose of measles vaccines. Vaccine. 2017 03 14; 35(12):1615-1621.
    View in: PubMed
    Score: 0.049
  22. Acute Demyelinating Events Following Vaccines: A Case-Centered Analysis. Clin Infect Dis. 2016 Dec 01; 63(11):1456-1462.
    View in: PubMed
    Score: 0.047
  23. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults. Vaccine. 2016 08 05; 34(36):4293-7.
    View in: PubMed
    Score: 0.047
  24. Safety of DTaP-IPV/Hib vaccine administered routinely to infants and toddlers. Vaccine. 2016 07 29; 34(35):4172-4179.
    View in: PubMed
    Score: 0.047
  25. Five-year Antibody Persistence and Booster Response After 1 or 2 Doses of Meningococcal A, C, W and Y Tetanus Toxoid Conjugate Vaccine in Healthy Children. Pediatr Infect Dis J. 2016 06; 35(6):662-72.
    View in: PubMed
    Score: 0.046
  26. Sudden-Onset Sensorineural Hearing Loss after Immunization: A Case-Centered Analysis. Otolaryngol Head Neck Surg. 2016 07; 155(1):81-6.
    View in: PubMed
    Score: 0.046
  27. Waning Tdap Effectiveness in Adolescents. Pediatrics. 2016 Mar; 137(3):e20153326.
    View in: PubMed
    Score: 0.045
  28. Differentiating Sepsis From Adverse Events After Immunization in the Neonatal Intensive Care Unit: How Is a Physician to Know? JAMA Pediatr. 2015 Aug; 169(8):718-9.
    View in: PubMed
    Score: 0.044
  29. Safety of measles-containing vaccines in 1-year-old children. Pediatrics. 2015 Feb; 135(2):e321-9.
    View in: PubMed
    Score: 0.042
  30. Effect of age on the risk of Fever and seizures following immunization with measles-containing vaccines in children. JAMA Pediatr. 2013 Dec; 167(12):1111-7.
    View in: PubMed
    Score: 0.039
  31. Long-term immune responses to pneumococcal conjugate vaccines in children previously vaccinated with 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013 Sep; 32(9):990-7.
    View in: PubMed
    Score: 0.038
  32. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013 Jul; 32(7):760-7.
    View in: PubMed
    Score: 0.038
  33. Incidence of genital warts in adolescents and young adults in an integrated health care delivery system in the United States before human papillomavirus vaccine recommendations. Sex Transm Dis. 2013 Jul; 40(7):534-8.
    View in: PubMed
    Score: 0.038
  34. Comparative effectiveness of acellular versus whole-cell pertussis vaccines in teenagers. Pediatrics. 2013 Jun; 131(6):e1716-22.
    View in: PubMed
    Score: 0.038
  35. Lack of association of Guillain-Barré syndrome with vaccinations. Clin Infect Dis. 2013 Jul; 57(2):197-204.
    View in: PubMed
    Score: 0.037
  36. Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med. 2012 Sep 13; 367(11):1012-9.
    View in: PubMed
    Score: 0.036
  37. Epidemiologic and clinical features of Bell's palsy among children in Northern California. Neuroepidemiology. 2012; 38(4):252-8.
    View in: PubMed
    Score: 0.035
  38. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine. 2012 Jun 06; 30(26):3929-36.
    View in: PubMed
    Score: 0.035
  39. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J. 2012 Jan; 31(1):64-71.
    View in: PubMed
    Score: 0.034
  40. An open-label, randomized, multi-center study of the immunogenicity and safety of DTaP-IPV (Kinrix™) co-administered with MMR vaccine with or without varicella vaccine in healthy pre-school age children. Vaccine. 2012 Jan 11; 30(3):668-74.
    View in: PubMed
    Score: 0.034
  41. Underimmunization at discharge from the neonatal intensive care unit. J Perinatol. 2012 May; 32(5):363-7.
    View in: PubMed
    Score: 0.033
  42. Evaluation of immunization rates and safety among children with inborn errors of metabolism. Pediatrics. 2011 May; 127(5):e1139-46.
    View in: PubMed
    Score: 0.032
  43. Post-marketing safety evaluation of a tetanus toxoid, reduced diphtheria toxoid and 3-component acellular pertussis vaccine administered to a cohort of adolescents in a United States health maintenance organization. Pediatr Infect Dis J. 2010 Jul; 29(7):613-7.
    View in: PubMed
    Score: 0.031
  44. Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. Pediatrics. 2010 Jul; 126(1):e1-8.
    View in: PubMed
    Score: 0.031
  45. Preterm infants' T cell responses to inactivated poliovirus vaccine. J Infect Dis. 2010 Jan 15; 201(2):214-22.
    View in: PubMed
    Score: 0.030
  46. Rates of autoimmune diseases in Kaiser Permanente for use in vaccine adverse event safety studies. Vaccine. 2010 Jan 22; 28(4):1062-8.
    View in: PubMed
    Score: 0.029
  47. Risk factors for developing apnea after immunization in the neonatal intensive care unit. Pediatrics. 2008 Mar; 121(3):463-9.
    View in: PubMed
    Score: 0.026
  48. Surveillance for invasive pneumococcal disease during 2000-2005 in a population of children who received 7-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2007 Sep; 26(9):771-7.
    View in: PubMed
    Score: 0.025
  49. A role for genetics in the immune response to the varicella vaccine. Pediatr Infect Dis J. 2007 Apr; 26(4):300-5.
    View in: PubMed
    Score: 0.025
  50. Role of Vaccine Age Restrictions on Rotavirus Vaccine Coverage, Vaccine Safety Datalink 2018-2024. J Pediatric Infect Dis Soc. 2026 Aug 04; 15(8).
    View in: PubMed
    Score: 0.023
  51. Estimated Effectiveness of 2024-2025 COVID-19 Vaccines in Adults. JAMA Intern Med. 2026 08 01; 186(8):976-986.
    View in: PubMed
    Score: 0.023
  52. Concordance Between Maternal and Infant COVID-19 and Influenza Vaccination Status. Pediatrics. 2026 Jul 01; 158(1).
    View in: PubMed
    Score: 0.023
  53. Influenza Activity and Estimated Vaccine Effectiveness During the 2025-2026 Influenza Season. JAMA Netw Open. 2026 Jun 01; 9(6):e2618581.
    View in: PubMed
    Score: 0.023
  54. Interim Estimated Effectiveness of 2025-2026 COVID-19 Vaccines in Adults Using a Test-Negative Design. JAMA Netw Open. 2026 Jun 01; 9(6):e2625152.
    View in: PubMed
    Score: 0.023
  55. Variability and gender differences in memory T cell immunity to varicella-zoster virus in healthy adults. Vaccine. 2006 Aug 14; 24(33-34):5913-8.
    View in: PubMed
    Score: 0.023
  56. SARS-CoV-2 Vaccination Before and During Pregnancy and Prevention of Infant COVID-19 Infection. Pediatrics. 2026 May 01; 157(5).
    View in: PubMed
    Score: 0.023
  57. Interim Estimates of 2025-26 Seasonal Influenza Vaccine Effectiveness - United States, September 2025-February 2026. MMWR Morb Mortal Wkly Rep. 2026 Mar 12; 75(9):116-123.
    View in: PubMed
    Score: 0.023
  58. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR Morb Mortal Wkly Rep. 2025 Dec 11; 74(40):607-614.
    View in: PubMed
    Score: 0.022
  59. In a shifting policy era: California provider knowledge and practice of medical exemption laws during the COVID-19 pandemic. Vaccine. 2026 Jan 01; 69:127993.
    View in: PubMed
    Score: 0.022
  60. Near real-time surveillance and tree-based data mining to assess the safety of respiratory syncytial virus vaccines in older adults in the vaccine safety datalink. Vaccine. 2025 Nov 20; 67:127873.
    View in: PubMed
    Score: 0.022
  61. Clinical immunization safety assessment (CISA) project: COVID-19 vaccine consultations and case reviews. Vaccine. 2025 Oct 24; 65:127781.
    View in: PubMed
    Score: 0.022
  62. Estimated 2023-2024 COVID-19 Vaccine Effectiveness in Adults. JAMA Netw Open. 2025 06 02; 8(6):e2517402.
    View in: PubMed
    Score: 0.022
  63. COVID-19 and Completion of Select Routine Childhood Vaccinations. Pediatrics. 2025 Apr 01; 155(4).
    View in: PubMed
    Score: 0.021
  64. Interim Estimates of 2024-2025 COVID-19 Vaccine Effectiveness Among Adults Aged =18 Years - VISION and IVY Networks, September 2024-January 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):73-82.
    View in: PubMed
    Score: 0.021
  65. Interim Estimates of 2024-2025 Seasonal Influenza Vaccine Effectiveness - Four Vaccine Effectiveness Networks, United States, October 2024-February 2025. MMWR Morb Mortal Wkly Rep. 2025 Feb 27; 74(6):83-90.
    View in: PubMed
    Score: 0.021
  66. Attitudes of California school personnel on potential COVID-19 vaccine mandates and state law SB277 to remove nonmedical vaccine exemptions. Vaccine. 2025 Apr 11; 52:126888.
    View in: PubMed
    Score: 0.021
  67. Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. Lancet. 2024 Oct 19; 404(10462):1547-1559.
    View in: PubMed
    Score: 0.021
  68. Trends in Gonorrhea and Chlamydia Testing and Infections Across the COVID-19 Pandemic in Adolescents and Young Adults in an Integrated Health System. J Adolesc Health. 2024 Dec; 75(6):952-957.
    View in: PubMed
    Score: 0.020
  69. Lack of Evidence for Vaccine-Associated Enhanced Disease From COVID-19 Vaccines Among Adults in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2024 08; 33(8):e5863.
    View in: PubMed
    Score: 0.020
  70. Ischemic Stroke After Bivalent COVID-19 Vaccination: Self-Controlled Case Series Study. JMIR Public Health Surveill. 2024 Jun 25; 10:e53807.
    View in: PubMed
    Score: 0.020
  71. COVID-19 Vaccination Coverage and Factors Associated With Vaccine Uptake Among People With HIV. JAMA Netw Open. 2024 Jun 03; 7(6):e2415220.
    View in: PubMed
    Score: 0.020
  72. COVID-19 Booster Vaccination in Early Pregnancy and Surveillance for Spontaneous Abortion. JAMA Netw Open. 2023 05 01; 6(5):e2314350.
    View in: PubMed
    Score: 0.019
  73. Estimation of COVID-19 mRNA Vaccine Effectiveness and COVID-19 Illness and Severity by Vaccination Status During Omicron BA.4 and BA.5 Sublineage Periods. JAMA Netw Open. 2023 03 01; 6(3):e232598.
    View in: PubMed
    Score: 0.018
  74. Extended surveillance to assess safety of 9-valent human papillomavirus vaccine. Hum Vaccin Immunother. 2022 12 30; 18(7):2159215.
    View in: PubMed
    Score: 0.018
  75. Effect of Electronic and Mail Outreach From Primary Care Physicians for COVID-19 Vaccination of Black and Latino Older Adults: A Randomized Clinical Trial. JAMA Netw Open. 2022 06 01; 5(6):e2217004.
    View in: PubMed
    Score: 0.018
  76. Waning 2-Dose and 3-Dose Effectiveness of mRNA Vaccines Against COVID-19-Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance - VISION Network, 10 States, August 2021-January 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 18; 71(7):255-263.
    View in: PubMed
    Score: 0.017
  77. A decade of data: Adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 02 23; 40(9):1246-1252.
    View in: PubMed
    Score: 0.017
  78. Evaluation of Trends in Homeschooling Rates After Elimination of Nonmedical Exemptions to Childhood Immunizations in California, 2012-2020. JAMA Netw Open. 2022 02 01; 5(2):e2146467.
    View in: PubMed
    Score: 0.017
  79. Association of the COVID-19 Pandemic With Routine Childhood Vaccination Rates and Proportion Up to Date With Vaccinations Across 8 US Health Systems in the Vaccine Safety Datalink. JAMA Pediatr. 2022 01 01; 176(1):68-77.
    View in: PubMed
    Score: 0.017
  80. The Childhood Vaccination Schedule and the Lack of Association With Type 1 Diabetes. Pediatrics. 2021 12 01; 148(6).
    View in: PubMed
    Score: 0.017
  81. Laboratory-Confirmed COVID-19 Among Adults Hospitalized with COVID-19-Like Illness with Infection-Induced or mRNA Vaccine-Induced SARS-CoV-2 Immunity - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1539-1544.
    View in: PubMed
    Score: 0.017
  82. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19-Associated Hospitalizations Among Immunocompromised Adults - Nine States, January-September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 05; 70(44):1553-1559.
    View in: PubMed
    Score: 0.017
  83. COVID-19 Vaccination and Non-COVID-19 Mortality Risk - Seven Integrated Health Care Organizations, United States, December 14, 2020-July 31, 2021. MMWR Morb Mortal Wkly Rep. 2021 Oct 29; 70(43):1520-1524.
    View in: PubMed
    Score: 0.017
  84. Safety and Immunogenicity of a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants in the United States. Pediatr Infect Dis J. 2021 10 01; 40(10):944-951.
    View in: PubMed
    Score: 0.017
  85. COVID-19 Vaccination Coverage Among Insured Persons Aged =16 Years, by Race/Ethnicity and Other Selected Characteristics - Eight Integrated Health Care Organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021 Jul 16; 70(28):985-990.
    View in: PubMed
    Score: 0.017
  86. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. N Engl J Med. 2021 07 15; 385(3):239-250.
    View in: PubMed
    Score: 0.016
  87. A Phase II Trial of Safety, Tolerability and Immunogenicity of V114, a 15-Valent Pneumococcal Conjugate Vaccine, Compared With 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants. Pediatr Infect Dis J. 2020 08; 39(8):763-770.
    View in: PubMed
    Score: 0.015
  88. Association Between Rotavirus Vaccination and Type 1 Diabetes in Children. JAMA Pediatr. 2020 05 01; 174(5):455-462.
    View in: PubMed
    Score: 0.015
  89. Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal Vaccinations. Pediatrics. 2020 03; 145(3).
    View in: PubMed
    Score: 0.015
  90. Near Real-Time Surveillance to Assess the Safety of the 9-Valent Human Papillomavirus Vaccine. Pediatrics. 2019 12; 144(6).
    View in: PubMed
    Score: 0.015
  91. Evaluation of two frailty indices, with practical application in a vaccine clinical trial. Hum Vaccin Immunother. 2019; 15(12):2960-2968.
    View in: PubMed
    Score: 0.014
  92. Incidence of Herpes Zoster Among Children: 2003-2014. Pediatrics. 2019 07; 144(1).
    View in: PubMed
    Score: 0.014
  93. Elimination of Nonmedical Immunization Exemptions in California and School-Entry Vaccine Status. Pediatrics. 2019 06; 143(6).
    View in: PubMed
    Score: 0.014
  94. Vaccine safety in HIV-infected adults within the Vaccine Safety Datalink Project. Vaccine. 2019 05 31; 37(25):3296-3302.
    View in: PubMed
    Score: 0.014
  95. Live Attenuated Influenza Vaccination Before 3 Years of Age and Subsequent Development of Asthma: A 14-year Follow-up Study. Pediatr Infect Dis J. 2018 05; 37(5):383-386.
    View in: PubMed
    Score: 0.013
  96. Rates and risk factors associated with hospitalization for pneumonia with ICU admission among adults. BMC Pulm Med. 2017 Dec 16; 17(1):208.
    View in: PubMed
    Score: 0.013
  97. Immunogenicity and Safety of the HZ/su Adjuvanted Herpes Zoster Subunit Vaccine in Adults Previously Vaccinated With a Live Attenuated Herpes Zoster Vaccine. J Infect Dis. 2017 12 12; 216(11):1343-1351.
    View in: PubMed
    Score: 0.013
  98. Patterns of childhood immunization and all-cause mortality. Vaccine. 2017 12 04; 35(48 Pt B):6643-6648.
    View in: PubMed
    Score: 0.013
  99. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine. Vaccine. 2017 12 14; 35(49 Pt B):6879-6884.
    View in: PubMed
    Score: 0.013
  100. Risk of venous thromboembolism following influenza vaccination in adults aged 50years and older in the Vaccine Safety Datalink. Vaccine. 2017 10 13; 35(43):5872-5877.
    View in: PubMed
    Score: 0.013
  101. Febrile Seizure Risk after Vaccination in Children One to Five Months of Age. Pediatr Neurol. 2017 Nov; 76:72-78.
    View in: PubMed
    Score: 0.013
  102. Maternal Tdap vaccination and risk of infant morbidity. Vaccine. 2017 06 22; 35(29):3655-3660.
    View in: PubMed
    Score: 0.012
  103. No association between influenza vaccination during pregnancy and adverse birth outcomes. Vaccine. 2017 05 31; 35(24):3186-3190.
    View in: PubMed
    Score: 0.012
  104. Assessing misclassification of vaccination status: Implications for studies of the safety of the childhood immunization schedule. Vaccine. 2017 04 04; 35(15):1873-1878.
    View in: PubMed
    Score: 0.012
  105. Time to Change Dosing of Inactivated Quadrivalent Influenza Vaccine in Young Children: Evidence From a Phase III, Randomized, Controlled Trial. J Pediatric Infect Dis Soc. 2017 Mar 01; 6(1):9-19.
    View in: PubMed
    Score: 0.012
  106. Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants. Pediatr Infect Dis J. 2017 02; 36(2):202-208.
    View in: PubMed
    Score: 0.012
  107. Identifying birth defects in automated data sources in the Vaccine Safety Datalink. Pharmacoepidemiol Drug Saf. 2017 Apr; 26(4):412-420.
    View in: PubMed
    Score: 0.012
  108. Febrile Seizure Risk After Vaccination in Children 6 to 23 Months. Pediatrics. 2016 07; 138(1).
    View in: PubMed
    Score: 0.012
  109. Absence of venous thromboembolism risk following quadrivalent human papillomavirus vaccination, Vaccine Safety Datalink, 2008-2011. Vaccine. 2016 Jan 02; 34(1):167-71.
    View in: PubMed
    Score: 0.011
  110. Risk of anaphylaxis after vaccination in children and adults. J Allergy Clin Immunol. 2016 Mar; 137(3):868-78.
    View in: PubMed
    Score: 0.011
  111. An Overview of Quadrivalent Human Papillomavirus Vaccine Safety: 2006 to 2015. Pediatr Infect Dis J. 2015 Sep; 34(9):983-91.
    View in: PubMed
    Score: 0.011
  112. Geographic clusters in underimmunization and vaccine refusal. Pediatrics. 2015 Feb; 135(2):280-9.
    View in: PubMed
    Score: 0.011
  113. Childhood vaccines and Kawasaki disease, Vaccine Safety Datalink, 1996-2006. Vaccine. 2015 Jan 03; 33(2):382-7.
    View in: PubMed
    Score: 0.010
  114. Timely versus delayed early childhood vaccination and seizures. Pediatrics. 2014 Jun; 133(6):e1492-9.
    View in: PubMed
    Score: 0.010
  115. Live vaccine use and safety in DiGeorge syndrome. Pediatrics. 2014 Apr; 133(4):e946-54.
    View in: PubMed
    Score: 0.010
  116. Protective association between rotavirus vaccination and childhood seizures in the year following vaccination in US children. Clin Infect Dis. 2014 Jan; 58(2):173-7.
    View in: PubMed
    Score: 0.010
  117. Factors that may explain observed associations between trivalent influenza vaccination and gastrointestinal illness in young children. Vaccine. 2013 Aug 20; 31(37):3894-8.
    View in: PubMed
    Score: 0.009
  118. Clinical assessment of serious adverse events in children receiving 2009 H1N1 vaccination. Pediatr Infect Dis J. 2013 Feb; 32(2):163-8.
    View in: PubMed
    Score: 0.009
  119. Adapting group sequential methods to observational postlicensure vaccine safety surveillance: results of a pentavalent combination DTaP-IPV-Hib vaccine safety study. Am J Epidemiol. 2013 Jan 15; 177(2):131-41.
    View in: PubMed
    Score: 0.009
  120. Causality assessment of adverse events reported to the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2012 Nov 26; 30(50):7253-9.
    View in: PubMed
    Score: 0.009
  121. Immunogenicity and safety of two tetravalent (measles, mumps, rubella, varicella) vaccines coadministered with hepatitis a and pneumococcal conjugate vaccines to children twelve to fourteen months of age. Pediatr Infect Dis J. 2012 Aug; 31(8):e133-40.
    View in: PubMed
    Score: 0.009
  122. Comparative immunogenicity and safety of different multivalent component pertussis vaccine formulations and a 5-component acellular pertussis vaccine in infants and toddlers: a randomized, controlled, open-label, multicenter study. Vaccine. 2012 May 14; 30(23):3360-8.
    View in: PubMed
    Score: 0.009
  123. Immunization and Bell's palsy in children: a case-centered analysis. Am J Epidemiol. 2012 May 01; 175(9):878-85.
    View in: PubMed
    Score: 0.009
  124. Recurrent Guillain-Barre syndrome following vaccination. Clin Infect Dis. 2012 Mar; 54(6):800-4.
    View in: PubMed
    Score: 0.009
  125. Causality assessment of serious neurologic adverse events following 2009 H1N1 vaccination. Vaccine. 2011 Oct 26; 29(46):8302-8.
    View in: PubMed
    Score: 0.008
  126. Immunogenicity and safety of an inactivated hepatitis A vaccine when coadministered with Diphtheria-tetanus-acellular pertussis and haemophilus influenzae type B vaccines in children 15 months of age. Pediatr Infect Dis J. 2011 Sep; 30(9):e164-9.
    View in: PubMed
    Score: 0.008
  127. Safety of trivalent inactivated influenza vaccine in children aged 24 to 59 months in the vaccine safety datalink. Arch Pediatr Adolesc Med. 2011 Aug; 165(8):749-55.
    View in: PubMed
    Score: 0.008
  128. Risk of rheumatoid arthritis following vaccination with tetanus, influenza and hepatitis B vaccines among persons 15-59 years of age. Vaccine. 2011 Sep 02; 29(38):6592-7.
    View in: PubMed
    Score: 0.008
  129. Understanding the role of human variation in vaccine adverse events: the Clinical Immunization Safety Assessment Network. Pediatrics. 2011 May; 127 Suppl 1:S65-73.
    View in: PubMed
    Score: 0.008
  130. The Vaccine Safety Datalink: a model for monitoring immunization safety. Pediatrics. 2011 May; 127 Suppl 1:S45-53.
    View in: PubMed
    Score: 0.008
  131. Attitudes and beliefs of parents concerned about vaccines: impact of timing of immunization information. Pediatrics. 2011 May; 127 Suppl 1:S120-6.
    View in: PubMed
    Score: 0.008
  132. Active surveillance for adverse events: the experience of the Vaccine Safety Datalink project. Pediatrics. 2011 May; 127 Suppl 1:S54-64.
    View in: PubMed
    Score: 0.008
  133. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine. 2010 Nov 23; 28(50):7865-72.
    View in: PubMed
    Score: 0.008
  134. Lack of association between acellular pertussis vaccine and seizures in early childhood. Pediatrics. 2010 Aug; 126(2):263-9.
    View in: PubMed
    Score: 0.008
  135. Real-time surveillance to assess risk of intussusception and other adverse events after pentavalent, bovine-derived rotavirus vaccine. Pediatr Infect Dis J. 2010 Jan; 29(1):1-5.
    View in: PubMed
    Score: 0.007
  136. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine. 2010 Jan 08; 28(3):657-63.
    View in: PubMed
    Score: 0.007
  137. Compliance with multiple-dose vaccine schedules among older children, adolescents, and adults: results from a vaccine safety datalink study. Am J Public Health. 2009 Oct; 99 Suppl 2:S389-97.
    View in: PubMed
    Score: 0.007
  138. Varicella vaccination and ischemic stroke in children: is there an association? Pediatrics. 2009 Feb; 123(2):e228-34.
    View in: PubMed
    Score: 0.007

© 2026 Kaiser Permanente

Your Privacy Choices